LGND News and Press, Ligand Pharmaceuticals Incorporated From 11/07/22

Ligand Pharmaceuticals, Inc. (LGND) Q3 2022 Earnings Conference Call November 07, 2022, 04:30 PM ET Company Participants Simon Latimer - Head, IR John Higgins - CEO Matthew Korenberg - President & CFO Octavio Espinoza - CFO Conference Call Participa...

Ligand Pharmaceuticals press release ( NASDAQ: LGND ): Q3 Non-GAAP EPS of $0.41 misses by $0.02 . Revenue of $66.09M (-4.0% Y/Y) beats by $27.76M . Ligand repurchased $38.6 million in principal amount of its 2023 Notes for $37.7 million in cash during the third...

Increased 2022 Financial Guidance Analyst and Investor Day to be Held on Tuesday December 13 in New York City Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for th...

Ligand Pharmaceuticals ( NASDAQ: LGND ) gained ~32% pre-market Wednesday after drug discovery company OmniAb ( OABI ) announced the completion of the spinoff from the biotech and subsequent merger with Avista Public Acquisition Corp. II. As a result, OmniAb ( OAB...

Ligand Shareholders Received 4.90007 Shares of OABI and 0.75842 OmniAb Earnout Shares for Each Share of LGND Regular-Way Trading of OABI Begins Tomorrow on Nasdaq Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the completion of its expected tax-free d...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the market volatility of 2022 opened doors for intriguing discounts, investors may want to consider allocating some of their funds toward undervalued biotech stocks. Fundamentally, the underlying industry represents t...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report third quarter 2022 financial results after the close of the U.S. financial markets on Monday, November 7, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will ...

First FDA approval of a bispecific antibody discovered using OmniAb technology OmniAb, Inc. is eligible to receive a $25 million milestone upon first commercial sale in the United States Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that Janssen Biotech, I...

APAC Shareholder Approval Obtained, Closing Scheduled for November 1, 2022 Ligand “Regular Way” and “Ex-Distribution” and OmniAb “When-Issued” Set to Begin Trading on October 25, 2022 Ligand Pharmaceuticals Incorporated (NASDAQ: LG...

COLUMBUS, Ohio, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today shared additional findings from its Evaluation...